Valuation: Charles River Laboratories International, Inc.

Market Cap 1.36TCr 1.19TCr 1.12TCr 1.02TCr 1.91TCr 1,30100Cr 1.92TCr 13TCr 5.18TCr 66TCr 5.11TCr 5TCr 2,14200Cr P/E 2026 *
77.9x
P/E 2027 * 32.6x
Enterprise Value 1.57TCr 1.37TCr 1.29TCr 1.18TCr 2.21TCr 1,50300Cr 2.21TCr 15TCr 5.98TCr 77TCr 5.9TCr 5.78TCr 2,47500Cr EV / Sales 2026 *
4.02x
EV / Sales 2027 * 3.81x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
17/09 Charles River Laboratories International Introduces Rapid Cell Banking Programs with Next-Generation Sequencing Characterization CI
17/09 Argus Research Adjusts Charles River Laboratories International PT to $330 From $250, Maintains Buy Rating MT
16/09 Charles River Laboratories to Provide Update on New Approach Methodologies Strategy on Investor Day, RBC Says MT
15/09 Charles River Laboratories International, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:40 AM
14/09 Charles River Laboratories International, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM
11/09 Evercore ISI Adjusts PT on Charles River Laboratories International to $320 From $300, Maintains Outperform Rating MT
08/09 Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite CI
21/08 Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing MT
20/08 Charles River, Medigen Partner on Multivalent Enterovirus Vaccine MT
20/08 Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing CI
14/08 Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing MT
10/08 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
10/08 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
1 day+2.19%
1 week+4.48%
Current month-1.09%
1 month-3.41%
3 months+57.03%
6 months+85.62%
Current year+42.93%
1 week 274.4
Extreme 274.4
290.11
1 month 267.27
Extreme 267.27
303.3
Current year 146.2
Extreme 146.195
303.3
1 year 144.26
Extreme 144.26
303.3
3 years 91.86
Extreme 91.8609
303.3
5 years 91.86
Extreme 91.8609
460.21
10 years 67.2
Extreme 67.2
460.21
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Exercice

Director

1,00,683 0.2090%
19/08/26 Don

Chief Executive Officer

-528 0.0011%
19/08/26 Exercice

Executive/Senior Manager

6,117 0.0127%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+4.48%+85.27%+42.83% 1.36TCr
-0.34%+4.16%+4.04%+29.78% 4.79TCr
+0.08%+0.16%+43.79%+35.89% 4.45TCr
+0.66%+6.23%+8.96%+93.14% 4.19TCr
+0.05%-5.86%+334.27%+542.87% 4.13TCr
-1.60%+0.56%+10.84%+46.93% 3TCr
+0.96%+1.56%+26.52%+159.67% 1.76TCr
-0.01%-0.92% - - 1.56TCr
-1.52%+4.04%+24.47%+41.98% 1.57TCr
-1.08%+12.11%-10.11% - 1.39TCr
Average +0.01%+2.84%+58.67%+124.14% 2.82TCr
Weighted average by Cap. -0.05%+2.14%+69.56%+137.93%

Financials

2026 *2027 *
Net sales 391.1Cr 341.78Cr 321.23Cr 293.14Cr 550.17Cr 37TCr 550.27Cr 3.86TCr 1.49TCr 19TCr 1.47TCr 1.44TCr 62TCr 400.05Cr 349.61Cr 328.58Cr 299.85Cr 562.77Cr 38TCr 562.87Cr 3.94TCr 1.52TCr 20TCr 1.5TCr 1.47TCr 63TCr
Net income 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 160.23Cr 62Cr 793.51Cr 61Cr 60Cr 2.56TCr 43Cr 38Cr 35Cr 32Cr 61Cr 4.12TCr 61Cr 424.65Cr 163.86Cr 2.1TCr 161.78Cr 158.23Cr 6.78TCr
Net Debt 211.22Cr 184.59Cr 173.49Cr 158.32Cr 297.13Cr 20TCr 297.19Cr 2.08TCr 803.45Cr 10TCr 793.23Cr 775.85Cr 33TCr 163.07Cr 142.51Cr 133.94Cr 122.23Cr 229.39Cr 16TCr 229.44Cr 1.61TCr 620.28Cr 7.96TCr 612.39Cr 598.97Cr 26TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
22/26/22 $285.11 +2.19% 11,37,111
21/26/21 $279.01 +0.34% 9,52,932
18/26/18 $278.06 -1.28% 14,81,168
17/26/17 $281.67 +3.02% 8,09,837
16/26/16 $273.41 +0.19% 10,14,795
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
285.11USD
Average target price
284.93USD
Spread / Average Target
-0.06%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!